热门资讯> 正文
Larimar Therapeutics GAAP每股收益为-0.34美元
2024-08-07 21:19
- Larimar Therapeutics press release (NASDAQ:LRMR): Q2 GAAP EPS of -$0.34.
- As of June 30, 2024, the Company had cash, cash equivalents and marketable securities totaling $226.1 million,
-
More on Larimar Therapeutics
- Larimar Therapeutics: More Data Still Needed
- Larimar: Stronger Buy Now More Than Ever After Partial Clinical Hold Completely Removed
- Larimar's Friedreich's ataxia asset nomlabofusp chosen for FDA accelerated program
- Biggest stock movers today: ZIM, XPEV, PANW, GOTU, and more
- Seeking Alpha’s Quant Rating on Larimar Therapeutics
风险及免责提示:以上内容仅代表作者的个人立场和观点,不代表华盛的任何立场,华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前,应结合自身情况,考虑投资产品的风险。必要时,请咨询专业投资顾问的意见。华盛不提供任何投资建议,对此亦不做任何承诺和保证。